Cargando…

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

OBJECTIVE: Toward the limited real-world data concerning the treatment response to brand direct-acting antiviral agents (DAAs) therapy, we proposed to evaluate the efficacy and safety of DAAs for the treatment of chronic hepatitis C virus (HCV) in mainland China. METHODS: In this retrospective, sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Huan, Lu, Chengzhen, Wang, Yin, Zaongo, Silvere D., Hu, Yue, Wu, Yue, Yan, Zhongfang, Ma, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248196/ https://www.ncbi.nlm.nih.gov/pubmed/32508646 http://dx.doi.org/10.3389/fphar.2020.00710

Ejemplares similares

Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis
por: Xia, Huan, et al.
Publicado: (2021)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
por: Nabulsi, Nadia A., et al.
Publicado: (2020)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
por: Xia, Huan, et al.
Publicado: (2020)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
por: El-Mahdy, Nageh Ahmed, et al.
Publicado: (2023)

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
por: Lee, Sun Hee, et al.
Publicado: (2020)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
por: Fang, Yu, et al.
Publicado: (2023)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
por: Kang, Yeo Wool, et al.
Publicado: (2021)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Progressive Multifocal Leukoencephalopathy Diagnosed by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid in an HIV Patient
por: Xia, Huan, et al.
Publicado: (2019)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
por: Imperatore, Nicola, et al.
Publicado: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
por: Mushtaq, Saima, et al.
Publicado: (2022)

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
por: Loo, Nicole, et al.
Publicado: (2019)

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea
por: Ghebremeskel, Ghirmay Ghebrekidan, et al.
Publicado: (2023)

The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
por: Alarfaj, Sumaiah J., et al.
Publicado: (2022)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
por: Zanaga, L.P., et al.
Publicado: (2019)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study
por: Gayam, Vijay, et al.
Publicado: (2018)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
por: Sundberg, Isak, et al.
Publicado: (2018)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
por: Yee, Jasmine, et al.
Publicado: (2021)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin
por: Zhang, Peiwen, et al.
Publicado: (2020)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fbgfgsvnrmagkugh484ttatf7c